marcusevans russia conferences

8th Generics and Biosimilars in Russia and EAEU

Successful Market Launch Strategies for Generic and Biosimilar Medicines in Russia and EAEU in the New Regulatory Landscape

21-23 Sep 2013
Moscow, Russian Federation

Conference Workshop

This interactive practical workshop will enable the participants to analyze Russian requirements to bioequivalence studies for biosimilars in comparison to European regulations and learn how to improve the efficiency of these studies
Workshop Moderator: Konstantin Zakharov // Artem Poltoratsky
Company: Deputy Director, Clinical Clinical Research, Scientific Research Center Eco-Safety // Head of the Department for Clinical Trials, Petrov Research Institute of Oncology

Why You Should Attend

8th Generics and Biosimilars in Russia and EAEU

Over the last few years the regulatory environment in Russia and EAEU has changed drastically. Alongside with the amendments to Russian regulations on development, clinical trials, registration and circulation of medicines, the EAEU Agreements are about to enter into force, which every so often disagree with local legislations. Generic and biosimilar medicines regulation raise even more questions. While the new regulatory initiatives are supposed to give the Russian companies new opportunities for business development, they become an obstacle for foreign pharmaceutical manufacturers. The companies now have to learn to deal with legislative collision and play their cards well to keep the market share and find opportunities for business development.

This premier 8th practical marcus evans conference will look at preparation of companies for business development in the new regulatory environment, effective market launch strategies for generic and biosimilar medicines and market expansion opportunities due to formation of EAEU common market.

Key practical case studies will delivered by AIPM, Pharmstandard, AstraZeneca, BIOCAD, Nanolek.

Key Topics

  • Evaluate prospectives for the development of generic and biosimilar markets in EAEU
  • Analyze new opportunities of Russian market for pharmaceutical manufacturers
  • Discuss pricing methods for VED
  • Ensure the quality of pharmaceutical substance for generic drugs manufacturing
  • Develop an IP strategy in accordance with market demands and regulatory requirements
  • Previous Attendees Include

    Abbott Laboratories, Abdi Ibrahim Global Pharm, Accell Clinical Research, Almirall S.A., Arterium, Association of the Russian Pharmaceutical Manufacturers (ARPM), Astellas Pharma Europe B.V MRO, Baxter, Bayer, Bayer Healthcare Pharmaceuticals, Besins Healthcare Rus LLC, Biocad, Biogen Idec, Bionika Media, Bionorica, Biorasi LLC, Brend Pharm, Center of Expertise and Clinical Trials, CJSC KPMG, CSL Behring AG, Develco Pharma GmbH, Elanco Animal Health, Eli Lilly, EurAsEC Committee, Ever Neyro Pharma, FARMAPLANT, Ferrer Internacional S.A, Formula- FR, Frensenius Medical Care Kazakhstan LLC, Fresenius Kabi Deutschland, Gedeon Richter Plc, Generium, Glaxosmithkline,
    Gorodissky & Partners, Jadran Galenski Laboratorij, Johnson&Johnson, Laboratoire Innotech International, Meabco A/S, Medisorb, Merck Serono, Nearmedic Plus Ltd,
    NTPharma, I.M. Sechenov First Moscow State Medical University, Nuvo Research GmbH, Parma Clinical, Pharm-Holding, Pharmindustry Kazakhstan Association, Pik-Pharma, Polpharma - Akrikhin, Probiotech, Reckitt Benckiser Healthcare, Roche Latvia, RUS Biopharm LLC, Solvay Interox Ltd, Stada, Standards of Pharmaceutical Market, Takeda, Teva, Teva Russia, Worwag Pharma GmbH & Co KG, Zentiva, Sanofi Company

    Why Choose marcus evans?

    marcus evans specialises in the research and development of strategic events for senior business executives. From our international network of 63 offices, marcus evans produces over 1000 event days a year on strategic issues in corporate finance, telecommunications, technology, health, transportation, capital markets, human resources and business improvement.

    Above all, marcus evans provides clients with business information and knowledge which enables them to sustain a valuable competitive advantage and makes a positive contribution to their success.

    Practical Insights From

    Roman Ivanov
    Deputy CEO for Biomedical Studies and Development

    Almira Galeeva
    Director of Clinical Research Ethical & Medical Affairs
    Association of International Pharmaceutical Manufacturers (AIPM)

    Alexander Ryzhkin
    R&D Director

    Lola Maksumova
    Vice President, Strategic Development

    Lilia Titova
    Executive Director
    The Union of Professional Pharmaceutical Organizations

    Oleg Mokhov
    Medical Director

    Sergey Mastyagin
    Marketing Manager RIA

    Click Here For Full Agenda

    Voice of Our Customers
    Join the Discussion

    Follow on LinkedIn

    Event Contact

    For all enquiries regarding speaking, sponsoring and attending this conference contact:

    Veronika Sapronova

    101 Finsbury Pavement
    EC2A 1ER

    +44 (0)20 3002 3435
    Fax: +44 (0)20 3002 3016